Drug Design & Development

Permanent URI for this collection

http://dspace.alquds.edu:4000/handle/20.500.12213/4755

Overview

The aim of this group is to investigate issues related to acces to health care services. Issue of human rights in health, financial socio-cultural barriers to care, stiga and health care access, quality of life, health coverage and access.

Our Team

    • Rafik Karaman

    Ph.D

    • Jehad Abbadi

    Ph.D.

    Mohannad Qurei

    Ph.D

    Mustafa Khamis

    Ph.D

    Browse

    Browsing Drug Design & Development by Subject "gastrointestinal complications"

    Now showing 1 - 1 of 1
    • Thumbnail Image
      Item
      Diclofenac Codrugs and Prodrugs-Three Decades of Design
      (‎WJPPS,Dr. T Pal, 2015-06-08) Dweib, khuloud; Jumaa, Salma; Thawabteh, Ameen; Scrano, Laura; Bufo, Sabino A.; Mecca, Gennaro; Karaman, Rafik
      Prodrugs or predrugs are inactive molecules which become active after in vivo conversion to release the active parent drug. The prodrug’s cleavage can be catalyzed by metabolic enzymes or can occur by chemical means without the involvement of enzymes. Prodrugs are designed to improve undesirable physicochemical and pharmacokinetic properties of their parent drugs. Non-steroidal anti-inflammatory (NSAIDs) drugs are among the most commonly used drugs for treatment of pain, inflammation and fever. Despite their frequent use, these agents suffer from gastrointestinal side effects that limit their use for those patients with gastrointestinal conditions. This mini review discusses the design, synthesis and pharmacological effects of prodrugs and codrugs of the non-steroidal anti-inflammatory (NSAIDs) Diclofenac sodium or potassium. It argues that the prodrug approach has the potential to eliminate Diclofenac associated gastrointestinal complications, increases its bioavailability and masks its bitter taste.